SB 202190 is a selective p38 MAP kinase inhibitor with IC50s of 50 nM and 100 nM for p38α and p38β2, respectively. SB 202190 binds to the ATP pocket of the active recombinant human p38 kinase with a Kd of 38 nM. SB 202190 has anti-cancer activity and rescued memory deficits
Statement:
->>Products covered by valid patents are not offered or supplied for commercial use.
->>Products currently covered by valid US Patents are offered for laboratory R&D use in accordance with 35 USC 271(e)+A13(1).
->>Any patent infringement and resulting liability is solely at buyer's risk.
->>Our products are only raw materials for drugs or industry, can't be used for human or animals directly.